INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

Allurion Technologies (NYSE:ALUR) reported Q2 2025 financial results and announced a strategic pivot focusing on low-dose GLP-1 combination therapy. Revenue was $3.4 million, down from $11.8 million in Q2 2024, primarily due to distributor transitions. The company reported a reduced operating loss of $7.0 million, a 26% improvement year-over-year.Key developments include a strategic partnership for manufacturing and R&D, including potential deve…

BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update – Ortho Spine News

MELVILLE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the second quarter ended June 30, 2025 and provided an update on its business. “We have continued to execute well across our business, including the achievement of key clinical program mile